REVELATION BIOSCIENCES, INC. (REVB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 17, 2026, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Revelation Biosc
How this was made
The 30-second read
Why it matters
The filing provides a primary disclosure of a routine equity compensation event with no material financial impact.
Market read
Low relevance; typical compensation filing for a micro‑cap biotech.
What to watch
Potential future dilution if many such awards are granted, but current size unknown.
Background
SEC Form 8‑K filing for Revelation Biosciences (ticker REVB) detailing a restricted stock award under its 2021 Equity Incentive Plan.
Ticker impact
Revelation Biosciences filed an 8‑K announcing a new restricted stock award to an employee under its 2021 Equity Incentive Plan.
minimal to none
No financial terms, size, or strategic change disclosed; typical for biotech micro‑caps.
Market effects
None; standard compensation practice in biotech sector.
None; company is US‑based with limited market footprint.
None
Counterpoint
If the grant signals upcoming talent retention ahead of a major trial, it could be a subtle bullish cue.
Key entities
- companyRevelation Biosciences, Inc.
Biotech firm filing the 8‑K.


